Posts tagged implant
Titan’s Probuphine featured on CBS affiliate

The CBS affiliate in Boston, WBZ-TV, has aired a segment about the opioid crisis, featuring Probuphine, a six-month implant developed by Titan Pharmaceuticals (NASDAQ:TTNP) that releases a steady dose of buprenorphine to provide maintenance treatment for opioid addiction.

Read More
Fortune hails Titan’s ProNeura technology has featured Titan Pharmaceuticals (NASDAQ:TTNP) and its ProNeura technology, calling it a “formidable new class of pharmaceutical implants.”

Read More
Titan’s Probuphine receives patient testimonial

A patient using Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant containing buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction has documented his experience on Janaburson’s Blog.

Read More
BTIG starts Organovo at buy

BTIG initiated coverage of Organovo Holdings (NASDAQ:ONVO) with a “buy” rating and $5 price target. The stock closed at $3.69 on Dec. 14.

Read More
Titan Pharma’s Kate Beebe interviewed on Facebook Live

Katherine Beebe, executive VP and chief development officer of Titan Pharmaceuticals (NASDAQ:TTNP), was interviewed on Facebook Live yesterday in conjunction with the company ringing the closing bell at the exchange.

Dr. Beebe discussed Titan’s Probuphine implant, which was approved by the FDA earlier this year for the treatment of opioid addiction, and its sales and marketing partner, Braeburn Pharmaceuticals.

Read More
Titan’s Probuphine gains more media attention

Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine six-month implant of sublingual buprenorphine continues to attract widespread media attention for its ability to treat addiction to opioids.

Independent TV station, WHDT, in Stuart, FL. has produced a segment on Probuphine with Dr. Stuart Segal and one of his patients, who was successfully weaned off her use of opioids.

Read More
Congress passes Comprehensive Addiction and Recovery Act

The United States Senate on Wednesday voted overwhelmingly to pass the Comprehensive Addiction and Recovery Act (CARA). The Senate vote follows a similar near-unanimous vote in the House of Representatives last week and will send the bill to the President for his signature.

The American Society of Addiction Medicine (ASAM) welcomed passage of the legislation and called on Congress to fulfill its commitment to fund CARA fully this year.

Read More
Braeburn provides update on training sessions for Probuphine

Healthcare provider training and certification for Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant will take place on July 15-17 in Denver by Titan’s marketing partner, closely-held Braeburn Pharmaceuticals.

The FDA cleared Probuphine in late May as the first implant for the maintenance treatment of opioid dependence in patients who have sustained clinical stability on low-to-moderate doses of buprenorphine, specifically 8 mg or less a day. Opioid use disorder is a chronic brain disease and one of the fastest growing public health epidemics in America.

Read More
Titan Pharma sensitivity analyses confirm efficacy of Probuphine

Titan Pharmaceuticals (NASDAQ: TTNP) is presenting data today from four post hoc sensitivity analyses of the final Phase 3 trial of Probuphine at a poster session during The College on Problems of Drug Dependence 78th Annual Meeting in Palm Springs.

Probuphine is a six-month subdermal buprenorphine implant for the long-term maintenance treatment of opioid dependence.

Read More
FDA approves Titan’s Probuphine implant for opioid dependence

The FDA has approved Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine.

“Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make new, innovative treatment options available that can help patients regain control over their lives,” said FDA commissioner Robert M. Califf, M.D. in a statement. “Today’s approval provides the first-ever implantable option to support patients’ efforts to maintain treatment as part of their overall recovery program.”

Read More
Titan Pharma’s Probuphine featured on CNBC

CNBC has highlighted Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine in a feature about the treatment of opioid addiction and the crisis of fatal overdoses in the U.S.

The feature discusses the potential benefits of an implant, compared with current sublingual versions of buprenorphine, and the relatively low percentage of doctors authorized to write prescriptions for buprenorphine.

Read More
Titan Pharma receives FDA feedback on Parkinson’s implant

The FDA has provided written feedback to Titan Pharmaceuticals (NASDAQ:TTNP) on the initial development plan for its proprietary ropinirole hydrochloride implant for Parkinson’s disease.

Based on the FDA’s feedback on the development plan submitted in December 2015, Titan is proceeding with the required non-clinical studies to support a potential IND submission in the fourth quarter of 2016, followed by an initial pharmacokinetic and proof-of-concept clinical study. Titan is pursuing a 505(b)(2) registration pathway for the implant.

Read More